Board of Directors
Kurt J. Hilzinger
Kurt J. Hilzinger was initially elected to the Board in July 2003, and was elected as Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director on Humana’s Board of Directors from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, LP, an independent private equity firm, having held this position since November 2007. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. Mr. Hilzinger also serves on the Board of Directors of Oncobiologics, Inc.
The Board believes that Mr. Hilzinger is a strong operating executive with a finance and strategic background, whose operational experience and financial expertise in the health care sector contributes valuable insight to the Board.
Frank Bisignano was initially elected to the Board in August 2017. He is the Chief Executive Officer at First Data, having held this position since 2013, and added the title of Chairman of the Board in 2014.
Under Bisignano, First Data enables electronic payments around the world, 3,000 times a second, for more than 6 million merchant locations, over 4,000 card issuers, and millions of consumers. As the payments industry leader, First Data gives its clients the tools they need to thrive in today’s fast-changing world. In 2017, the company processed more than 93 billion electronic transactions worldwide representing $2.4 trillion in transaction volume. Headquartered in Atlanta, First Data operates in 34 countries spanning the globe. The company’s 2017 consolidated revenue was $12 billion.
Upon his arrival at First Data, Bisignano began to rapidly transform the 47-year-old company from its position as the world’s largest traditional payment processor into a technology innovator, industry collaborator, and commerce enabler for the 21st Century.
Bisignano’s first big move as CEO was launching an equity ownership plan turning First Data's 22,000 employees into shareholders. In his early days, he steered the rollout of Clover Station, a breakthrough point-of-sale platform designed for small and midsized businesses to track inventory, manage employees, build lasting customer relationships, and accept the full array of payments, from cash to Apple Pay. The spirit of a technology company soon took hold as Bisignano partnered with, or acquired, leading startups to further strengthen First Data’s portfolio of cutting-edge solutions and services.
In June 2014, First Data announced an historic $3.5 billion private placement of equity which began a deleveraging effort that continues today. The private placement was followed by a $2.6 billion IPO in October 2015, the largest U.S. IPO of the year. These transactions, along with substantial refinancing of First Data’s debt, ratified the transformation begun under Bisignano’s leadership and set the course for First Data’s future. In May 2017, that new course forged ahead with the acquisition of CardConnect for $750 million, the company’s largest such deal in thirteen years.
Prior to joining First Data, Bisignano was the co-chief operating officer for J.P. Morgan Chase and the chief executive officer of its Mortgage Banking unit. As co-COO, Bisignano's responsibilities included overseeing global technology, human resources, real estate, operations, procurement, compliance, regulatory control and oversight, resiliency, security and safety, and general services for all of J.P. Morgan Chase’s businesses in over 60 countries. Under Bisignano’s leadership, the Mortgage Banking unit reported 2012 net income of $3.3 billion, a turnaround that reversed a net loss of $2.1 billion in the prior year.
Earlier in his career, Bisignano held several roles at Citigroup that included serving on the bank’s management committee and roles as chief administrative officer for the Corporate and Investment Bank and CEO of Citigroup's Global Transactions Services business. While CAO, Bisignano also served as the firm-wide deputy head of technology and operations, a post he held during 9/11, when he deployed and ran Citigroup's business continuity plan. The plan required emergency relocation of 16,000 employees displaced by the loss of 7 World Trade Center, which was crippled by the terrorist attack. In later years at Citi, as CEO of the bank’s Global Transactions Services business from 2002–2005, Bisignano’s unit’s revenue grew to $6 billion from $4 billion annually, with bottom line performance swinging from a net income loss of $400 million to a profit in excess of $1 billion during his tenure.
During his tenure at Citi, which began in 1994, Bisignano played a key role in a series of historic transactions as he took on more senior roles. These deals included the merger of Citicorp and Travelers and the acquisitions of Salomon-Smith Barney and Primerica Financial Services, among others.
Before Citi, Bisignano worked at First Fidelity Bank from 1990 to 1994, where he was an executive vice president overseeing technology and operations, and later served as chief consumer lending officer. At First Fidelity, Bisignano earned a reputation for skillfully managing complex mergers and integrations, overseeing 13 acquisitions into the business and consolidating eight banks into one.
Throughout his career, Bisignano has worked to create career opportunities for men and women who served in uniform. While at J.P. Morgan Chase, he was a founder of the 100,000 Jobs Mission, an original coalition of 11 companies that has since grown to a roster of 170 firms, hiring more than 395,000 veterans as of April 2017. Bisignano’s commitment to veterans has continued at First Data, where the First Data Salutes program provides broad opportunities and support for returning military and their families.
A strong supporter of diversity, Bisignano also helped create seven new employee resource groups at First Data, earning the company a roster of accolades for its efforts, ranging from veterans’ groups to the lesbian, gay, bisexual and transgender (LGBT) community.
Bisignano is a member of the Board of Directors of Humana Inc. Among his non-profit commitments, he serves on the boards of the Partnership for New York City, the National September 11 Memorial and Museum, The Perelman Center for Performing Arts at the World Trade Center, the Mount Sinai Health System, the advisory board for the Institute for Veterans and Military Families (IVMF), St. Patrick’s Cathedral, and The Battery Conservancy. In addition to being a Centennial Society member of The Economic Club of New York, he also serves on the boards of the Metro Atlanta Chamber and The Commerce Club of Atlanta. Bisignano was previously vice chairman of the Options Clearing Corporation and a board member for the Depository Trust and Clearing Corporation, the Alliance for Downtown New York, the Lower Manhattan Cultural Council, and PENCIL.
In 2010, Bisignano was awarded Syracuse University’s Chancellor's Medal for Outstanding Achievement for his innovation in technology and education. In 2014, Bisignano received the Colonel Michael Endres Leadership Award for Individual Excellence in Veteran Employment from the U.S. Chamber of Commerce. The New York Institute of Technology honored Bisignano in May 2014 with a Doctor of Commercial Science degree for his achievements in business and his philanthropic endeavors. In May 2017, Syracuse University bestowed Bisignano with an Honorary Doctorate of Law degree for his distinguished business career and his work in championing higher education and supporting the disadvantaged.
Bisignano was born and raised in Brooklyn, New York. He has three children, Morgan, Alexa, and Henry. He and his wife, Tracy, reside in New Jersey.
Bruce D. Broussard
Bruce D. Broussard, President and CEO, joined Humana in 2011. Under his leadership, Humana has created an integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member experience. With its holistic approach, Humana is dedicated to improving the health of the communities it serves by making it easy for people to achieve their best health.
Bruce brings to Humana a wide range of executive leadership experience in publicly traded and private organizations within a variety of healthcare sectors, including oncology, pharmaceuticals, assisted living/senior housing, home care, physician practice management, surgical centers and dental networks.
Prior to joining Humana, Bruce was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Bruce served in a number of senior executive roles, including Chief Financial Officer, President, Chief Executive Officer and Chairman of the Board.
Bruce plays a leadership role in key business advocacy organizations such as The Business Council and the American Heart Association CEO Roundtable. He is also a member of the Board of Directors of KeyCorp and the World Economic Forum Health Governors Board.
Frank A. D'Amelio
Frank A. D'Amelio was initially elected to the Board in September 2003. He is Executive Vice President, Business Operations and Chief Financial Officer of Pfizer Inc, having held this position since December 2010, and having served as Chief Financial Officer since September 2007. Prior to that, Mr. D’Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent from December 2006 to August 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent. Mr. D’Amelio also serves on the Board of Directors of Zoetis, Inc. and on the board of the Independent College Fund of New Jersey.
The Board believes that Mr. D’Amelio’s skills, global experience and proven leadership in both financial and operational roles contribute greatly to the Board’s composition. As a senior executive at various global companies undergoing the kind of rapid and complex changes that the Company has undertaken in response to the rapidly changing markets and regulatory environment, Mr. D’Amelio has extensive knowledge of the capital markets as well as broad experience working with the investment community, regulatory bodies and rating agencies.
Karen DeSalvo MD, MPH, MSc
Karen DeSalvo, MD, MPH, MSc is a physician whose career has been dedicated to improving the health of all people, with a particular focus on vulnerable populations, through patient care, education, policy and administrative roles, research, and public service. Her commitment to improving the public’s health includes ensuring access to quality, affordable health care, strengthening the public health infrastructure, and creating public-private partnerships to address the social determinants of health.
Dr. DeSalvo most recently served as Acting Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS), a position President Barack Obama nominated her for in May of 2015. In that role, she oversaw 12 core public health offices and 10 regional health offices across the nation, and the development of public health policy recommendations, most notably Public Health 3.0 - a blue print for the future of public health. Under Dr. DeSalvo’s leadership as Delivery System Reform strategy co-lead, HHS set and met historic goals in payment reform, supported transformed models of care delivery including in primary care, and changed the approach to information distribution in the health system.
She also served as the National Coordinator for Health Information Technology; a role in which she was responsible for setting federal and national strategy and policy. She focused national attention on the need to move beyond adoption and focus on interoperability. She marshaled public and private stakeholders to create and execute on a national strategy to health IT that shifts focus from electronic health records to standardized data, freed through requiring published APIs(application programmable interfaces) and effectuating a culture and business case for information flow to support better health for individuals and communities.
Before joining HHS, Dr. DeSalvo was New Orleans Health Commissioner. While there, she transformed the outmoded health department to one that has since achieved national accreditation and recognition, restored health care to devastated areas of the city, and led the establishment of a public hospital. Following Hurricane Katrina, she was a community leader in building an innovative and award-winning model of neighborhood-based community health services for low-income, uninsured and other vulnerable people in the New Orleans area.
Dr. DeSalvo was previously professor of medicine and vice dean for community affairs and health policy at the Tulane School of Medicine. Her accomplishments have earned her numerous leadership awards and accolades, including the “Surgeon General’s Medallion,” the highest honor bestowed by the United States Public Health Service, for actions of exceptional achievement for the cause of public health and medicine and election to the National Academy of Medicine. Dr. DeSalvo earned her Medical Doctorate and Master’s in Public Health from Tulane University, and Master's in Clinical Epidemiology from Harvard School of Public Health.
W. Roy Dunbar
W. Roy Dunbar was initially elected to the Board in April 2005. Mr. Dunbar was the Chairman of the Board of NetworkSolutions, and was the Chief Executive Officer from January 2008 to November 2009. Mr. Dunbar also served as the President of Global Technology and Operations for MasterCard Incorporated from September 2004 until January 2008. Mr. Dunbar worked at Eli Lilly and Company for 14 years, latterly as President of Intercontinental Operations from 2003 until he joined MasterCard, and Chief Information Officer from 1999 to 2003.
The Board believes that Mr. Dunbar’s innovative, consumer-focused approach to information technology at a variety of global companies brings a valuable advantage to the Board. The Board benefits from Mr. Dunbar’s expertise in leading companies focused on the development of information systems that are easy for consumers to understand and use effectively, which is critical to the Company’s extension of its position as a leader in health care information technology. Mr. Dunbar’s extensive experience in health care over three decades further contributes to the strategic composition of the Board.
David A. Jones Jr.
David A. Jones, Jr. was initially elected to the Board in May 1993 and served as Chairman of the Board of the Company from April 2005 through August 2010, and Vice Chairman of the Board from September 1996 through April 2005. He is Chairman of Chrysalis Ventures, LLC, headquartered in Louisville, Kentucky, and also serves on the Board of Directors of Connecture, Inc. (NASDAQ: CNXR) and MyHealthDirect, Inc.
As a successful venture capitalist, the Board believes that Mr. Jones brings strategic insight and leadership and a wealth of experience in health care to the Board, both in the Company’s core businesses as well as in emerging technologies and business models.
William J. McDonald
William J. McDonald was initially elected to the Board in October 2007. Mr. McDonald is the managing partner of Wild Irishman Advisory, LLC, a marketing consulting firm. Prior to that, McDonald was Executive Vice President, Brand Management of Capital One Financial Corporation, having held that position from 1998 until his retirement in 2013. Prior to joining Capital One, he served as chief marketing officer for Boston Chicken, Inc. Previously, he was chief marketing officer for KFC and also served in marketing and branding leadership roles for Pizza Hut and PepsiCo.
The Board believes that Mr. McDonald’s service in various senior executive marketing positions contributes significant experience and expertise in brand development, marketing and related disciplines.
William E. Mitchell
William E. Mitchell is the Founding Partner of Sequel Venture Partners, LLC (formerly Sequel Capital Management, LLC), formed in January, 2010 to provide transformational capital, breakthrough strategic thinking and management expertise to innovative companies ranging from early stage start-ups to mid-level enterprises, primarily in the technology sector.
Prior to this, Mr. Mitchell was Chairman of the Board and Chief Executive Officer of Arrow Electronics, Inc. (NYSE: ARW), a 20B$ Fortune 150 company providing distribution and advanced supply chain solutions to the technology industry. He joined Arrow in February 2003 as President and Chief Executive Officer, was named Chairman of the Board in May 2006, and retired as Chairman of the Board and Chief Executive Officer in January 2010.
Mr. Mitchell began his career at Raychem Corporation, where he spent 20 years in various roles in finance, manufacturing, international operations, and worldwide sales and marketing. In 1993, he was named President and Chief Executive Officer of Nashua Corporation, a manufacturer of specialty products and services for print application needs. In 1995, he became Chairman, President and Chief Executive Officer of Sequel, Inc., then a privately held computer services company. Prior to joining Arrow, Mr. Mitchell led the acquisition of Sequel, Inc. by Solectron Corporation, and then led the successful formation of Solectron Global Services, a 1.2B$ technology services company, now part of Flextronics International.
The Board believes that Mr. Mitchell’s insights and experience running a complex global public company, as well as his significant experience in the governance of large publicly-traded corporations, will be valuable in helping to guide the Company in the years ahead.
David B. Nash, M.D.
David B. Nash, M.D. was initially elected to the Board in December 2009, effective January 1, 2010. He is the founding dean of the Jefferson School of Population Health, located on the campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008. Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College from 2003 until 2008. Dr. Nash also serves on the Board of Directors of Vestagen Specialty Textiles, and the medical advisory board of Medivo, Inc., and previously served on the boards of Itrax Corporation and InforMedix.
Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement; his publications have appeared in more than 100 articles in major journals. He also has served as a member of the Board of Trustees of Catholic Healthcare Partners in Cincinnati, Ohio.
The Board believes that Dr. Nash brings a unique and compelling set of attributes that enhance the Company’s ability to help people achieve lifelong well-being. As a widely recognized innovator in an emerging medical discipline that unites population health, health policy, and individual health, Dr. Nash is internationally recognized for his work in outcomes management, medical staff development and quality-of-care improvement.
James J. O'Brien
James J. O'Brien was initially elected to the Board in April 2006. Mr. O’Brien retired as Chairman of the Board and Chief Executive Officer of Ashland Inc. effective December 31, 2014, having served in that role since 2002. Prior to that, Mr. O’Brien was President and Chief Operating Officer of Ashland Inc., and before that, Senior Vice President and Group Operating Officer. He currently serves on the Boards of Albemarle Corporation, Wesco International, Inc. and Eastman Chemical Company.
As a highly respected leader in the global business community with an extraordinary track record of success, the Board believes that Mr. O’Brien’s breadth of management experience adds valuable expertise and insight to the Board.
Marissa T. Peterson
Marissa T. Peterson was initially elected to the Board in August 2008. Ms. Peterson was formerly Executive Vice President, Worldwide Operations, Services & Customer Advocacy for Sun Microsystems Inc. in Santa Clara, California, until her retirement in 2005 after 17 years with the company. She currently runs an executive coaching practice focused on helping grow and develop leaders in the high-technology space. Ms. Peterson currently serves as the Chairman of the Board for Oclaro Inc., and on the Board of Directors of Ansell, Limited, and previously served on the board of directors of SUPERVALU INC., and Lucile Packard Children’s Hospital at Stanford, and the board of trustees of Kettering University. Ms. Peterson holds an honorary doctorate in management and a bachelor’s degree in engineering from Kettering University where she graduated magna cum laude. She received her MBA from Harvard Business School with the distinction of being a GM Fellow.
The Board believes that Ms. Peterson’s operating and consumer-focused leadership, and experience developing and managing programs designed to help companies reduce the time, cost and risk of transforming their businesses by leveraging technology to architect, implement and maintain customers’ network computing infrastructures, bring valuable insights to the Board. Her commitment to a “customer first” ethic at Sun Microsystems Inc. established an industry leadership position for high quality and cost-effective product execution to a global customer base, a commitment that aligns with the Company’s focus on consumerism.